Vigil Neuroscience (VIGL) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Company vision and strategy

• Focuses on developing microglia-targeted therapeutics for rare and common neurodegenerative diseases, emphasizing a precision-based approach to neuroinflammation.

• Differentiates itself with two TREM2 modalities: a monoclonal antibody in Phase II for ALSP and a first-in-class small molecule TREM2 agonist in Phase I for Alzheimer's disease.

• Strategic partnership with Sanofi includes a $40 million investment and right of first negotiation on the small molecule program, extending financial runway into 2026.

• Building a microglia biology platform to expand the pipeline and target additional indications.

ALSP program and clinical insights

• ALSP is a rare, inherited neurodegenerative disease linked to CSF1R mutations, with TREM2 agonism hypothesized to compensate for CSF1R deficiency.

• Recent data suggest ALSP prevalence is higher than previously thought, with up to 19,000 cases in the US and 29,000 in Europe and the UK.

• The ILLUMINATE natural history study identified MRI as the most sensitive and dynamic biomarker, correlating with cognitive decline and supporting its use as a surrogate endpoint.

• Early interim Phase II IGNITE data showed excellent safety, increased antibody penetration in active disease, and biomarker improvements, with full 12-month data expected in the first half of next year.

• FDA discussions have left the door open for accelerated approval, with MRI as a potential surrogate endpoint.

TREM2 small molecule program and future plans

• The oral TREM2 agonist is highly CNS penetrant, synergizes with natural damage ligands, and is positioned for larger indications like Alzheimer's disease.

• Interim Phase I SAD data showed strong safety, tolerability, PK supporting daily dosing, and robust PD response with sustainable reduction in soluble TREM2.

• The final Phase I data, including SAD, MAD, AD, and elderly cohorts, is expected in the first quarter of next year.

• Ongoing studies aim to inform Phase II design by evaluating biomarker responses across subpopulations.